Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,616 | 141 | 84.9% |
| Education | $371.54 | 11 | 8.7% |
| Travel and Lodging | $271.00 | 3 | 6.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $955.75 | 40 | $0 (2022) |
| Lilly USA, LLC | $740.62 | 28 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $377.03 | 16 | $0 (2018) |
| GlaxoSmithKline, LLC. | $351.08 | 15 | $0 (2022) |
| Axsome Therapeutics, Inc. | $263.84 | 3 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $223.90 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $178.59 | 10 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $164.46 | 4 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $158.33 | 2 | $0 (2024) |
| Alkermes, Inc. | $157.14 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $940.90 | 24 | Axsome Therapeutics, Inc. ($263.84) |
| 2023 | $200.78 | 4 | ITI, Inc. ($148.59) |
| 2022 | $366.84 | 8 | Lilly USA, LLC ($271.00) |
| 2021 | $150.93 | 8 | GlaxoSmithKline, LLC. ($77.68) |
| 2020 | $720.78 | 25 | Novo Nordisk Inc ($319.11) |
| 2019 | $415.69 | 14 | Novo Nordisk Inc ($212.73) |
| 2018 | $604.75 | 25 | Novo Nordisk Inc ($281.37) |
| 2017 | $857.37 | 47 | Lilly USA, LLC ($340.92) |
All Payment Transactions
155 individual payment records from CMS Open Payments — Page 7 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/01/2017 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/25/2017 | SANOFI-AVENTIS U.S. LLC | SOLIQUA (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: DIABETES | ||||||
| 01/23/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Diabetes | ||||||
| 01/19/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $3.40 | General |
| Category: Diabetes | ||||||
| 01/11/2017 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Drug) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 100 | 122 | $14,505 | $8,347 |
| 2021 | 3 | 170 | 251 | $28,090 | $19,139 |
| 2020 | 3 | 233 | 345 | $37,090 | $22,310 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 37 | 37 | $6,475 | $4,605 | 71.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 66 | $5,940 | $2,775 | 46.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 19 | $2,090 | $967.22 | 46.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 72 | 72 | $11,280 | $9,053 | 80.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 67 | 144 | $12,960 | $7,624 | 58.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 31 | 35 | $3,850 | $2,463 | 64.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 92 | 92 | $13,340 | $10,131 | 75.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 98 | 204 | $18,360 | $8,536 | 46.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 43 | 49 | $5,390 | $3,643 | 67.6% |
About Dr. Kenneth Baker, DO
Dr. Kenneth Baker, DO is a General Practice healthcare provider based in Norridgewock, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407930068.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Baker, DO has received a total of $4,258 in payments from pharmaceutical and medical device companies, with $940.90 received in 2024. These payments were reported across 155 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($3,616).
As a Medicare-enrolled provider, Baker has provided services to 503 Medicare beneficiaries, totaling 718 services with total Medicare billing of $49,796. Data is available for 3 years (2020–2022), covering 9 distinct procedure/service records.
Practice Information
- Specialty General Practice
- Location Norridgewock, ME
- Active Since 10/24/2006
- Last Updated 11/01/2007
- Taxonomy Code 208D00000X
- Entity Type Individual
- NPI Number 1407930068
Products in Payments
- Ozempic (Drug) $452.95
- Auvelity (Drug) $263.84
- TRULICITY (Drug) $236.23
- TOUJEO (Drug) $218.37
- TRELEGY ELLIPTA (Drug) $211.05
- JARDIANCE (Drug) $187.85
- FARXIGA (Drug) $178.59
- CAPLYTA (Drug) $161.76
- COBENFY (Drug) $158.33
- Victoza (Drug) $149.51
- SOLIQUA (Drug) $119.27
- VRAYLAR (Drug) $111.95
- XARELTO (Drug) $105.98
- ENTRESTO (Drug) $104.66
- FANAPT (Drug) $100.07
- INVOKANA (Drug) $96.00
- ANORO ELLIPTA (Drug) $82.77
- LYBALVI (Drug) $78.26
- ARISTADA (Drug) $51.01
- REXULTI (Drug) $47.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.